Blood glucose concentration and risk of pancreatic cancer: Systematic review and dose-response meta-analysis

BMJ (Online)

Volumn 349, Issue , 2015, Pages

  Liao, Wei Chih ^a,b   Tu, Yu Kang ^b   Wu, Ming Shiang ^a   Lin, Jaw Town ^c   Wang, Hsiu Po ^a   Chien, Kuo Liong ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL;

ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE MODIFICATION; OBSERVATIONAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; ANALYSIS; BIOMETRY; BLOOD; COMPLICATION; EARLY DIAGNOSIS; HEALTH BEHAVIOR; HYPERGLYCEMIA; META ANALYSIS; PANCREATIC NEOPLASMS; PREDIABETIC STATE; PSYCHOLOGY; STATISTICS;

BIOMETRY; BLOOD GLUCOSE; EARLY DIAGNOSIS; HEALTH BEHAVIOR; HUMANS; HYPERGLYCEMIA; OBSERVATIONAL STUDIES AS TOPIC; PANCREATIC NEOPLASMS; PREDIABETIC STATE; RISK FACTORS; STATISTICS AS TOPIC;

EID: 84930220817     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g7371     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Cancer Research UK. Cancer mortality for common cancers. www.cancerresearchuk.org/cancer-info/cancerstats/mortality/cancerdeaths/.
3. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009;6:699-708.
4. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012;51:64-74.
5. Andersen DK. Diabetes and cancer: placing the association in perspective. Curr Opin Endocrinol Diabetes Obes 2013;20:81-6.
6. Huxley R, Ansary-Moghaddam A, Berrington De Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-83.
7. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85.
8. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
9. Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010;53:21-6.
10. Han L, Ma Q, Li J, Liu H, Li W, Ma G, et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One 2011;6:8.
11. Li J, Ma Q, Liu H, Guo K, Li F, Li W, et al. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS One 2011;6:0017385.
12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
13. Powers AC. Diabetes Mellitus. In: Longo DL FA, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine. 18th ed. McGraw-Hill, 2012.
14. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. www.cdc.gov/diabetes/pubs/factsheets.htm.
15. Nathan DM, Davidson MB, De Fronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-9.
16. Sicree R, Shaw J, Zimmet P. The global burden. Diabetes and impaired glucose tolerance. IDF Diabetes Atlas. 4th ed. International Diabetes Federation, 2009:1-105.
17. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
18. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
19. Ansary-Moghaddam A, Huxley R, Barzi F, Lawes C, Ohkubo T, Fang X, et al. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomarkers Prev 2006;15:2435-40.
20. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872-8.
21. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000;283:2552-8.
22. Batty GD, Shipley MJ, Marmot M, Smith GD. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control 2004;15:873-81.
23. Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009;18:240-7.
24. Grote VA, Rohrmann S, Nieters A, Dossus L, Tjonneland A, Halkjaer J, et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia; 54:3037-46.
25. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202.
26. Johansen D, Stocks T, Jonsson H, Lindkvist B, Bjorge T, Concin H, et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580, 000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev 2010;19:2307-17.
27. Greenland S. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology 1995;6:450-4.
28. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012;175:66-73.
29. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010;29:1037-57.
30. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
31. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 2012;20:20.
32. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008;134:981-7.
33. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013;10:423-33.
34. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.medicine.mcgill.ca/rtamblyn/Readings%5CThe%20Newcastle%20-%20Scale%20for%20assessing%20the%20quality%20of%20nonrandomised%20studies%20in%20meta-analyses.pdf.
35. Kumaravel B, Bachmann MO, Murray N, Dhatariya K, Fenech M, John WG, et al. Use of haemoglobin A1c to detect impaired fasting glucose or type 2 diabetes in a United Kingdom community based population. Diabetes Res Clin Pract 2012;96:211-6.
36. Cryer PE, David SN. Hypoglycemia. In: Longo DL FA, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison's principles of internal medicine. McGraw-Hill, 2012.
37. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
38. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
39. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
40. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301-9.
41. White IR. Multivariate random-effects meta-analysis. Stata J 2009;9:40-56.
42. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006;6:40-57.
43. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, et al. Hyperglycemia, insulin resistance, impaired pancreatic ß-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 2013;105:1027-35.
44. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993;22:1189-92.
45. Regel I, Kong B, Raulefs S, Erkan M, Michalski CW, Hartel M, et al. Energy metabolism and proliferation in pancreatic carcinogenesis. Langenbecks Arch Surg 2012;397:507-12.
46. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
47. Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, Di Maio D, et al. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS One 2012;7:7.
48. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
49. Balkau B, Barrett-Connor E, Eschwege E, Richard JL, Claude JR, Ducimetiere P. Diabetes and pancreatic carcinoma. Diabete Metab 1993;19:458-62.
50. Hiatt RA, Klatsky AL, Armstrong MA. Pancreatic cancer, blood glucose and beverage consumption. Int J Cancer 1988;41:794-7.